NCT03892525 2021-07-26
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 1 Terminated
Clinical Trials
6 trialsNCT01103635 2020-04-07
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02225002 2018-08-28
Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01456585 2018-08-27
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02157831 2018-08-17
Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT01008527 2015-09-24
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed